AntriaBio appoints Barry Sherman to board
This article was originally published in Scrip
Executive Summary
AntriaBio, a biopharmaceutical company focused on developing treatments for diabetes and metabolic diseases, has named Dr Barry Sherman to its board of directors. Notably, Dr Sherman was the first chief medical officer of Genentech in the mid-1990s following his role directing Genentech's clinical research and medical affairs teams. He has also served as president and CEO of StemPar Sciences, president and CEO of Anergen Inc, a founder of Pain Therapeutics, and the executive vice-president and co-founder of BiPar Sciences.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.